Tufts: CROs investing more in tech, beating sponsors on site-related timelines

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/YiuCheung)
(Image: Getty/YiuCheung)

Related tags: Investment

Technology investments are catalyzing the study start-up process – and with more investment coming in from CROs, sponsors complete all site-related activity 6 to 11 weeks slower, according to a recent Tufts report.

The study start-up process averages 5 to 6 months in duration, though 11% of sites are never activated, according to a report by the Tufts Center for the Study of Drug Development (CSDD)​, which surveyed pharmaceutical organizations, biotech companies, and contract research organizations (CROs) to assess start-up practices and performance.

The research was supported by a grant from goBalto, a San Francisco, CA-based developer of web-based clinical research solutions.

As stakeholders are increasingly aware that better study start-up processes are linked to shorter clinical timelines, the emphasis has been shifting in that direction​,” said Sujay Jadhav, goBalto CEO. “The increasing use of technology and impact on cycle time reductions is a very positive industry trend​.”

According to the report, 80% of respondents who invested in technology reported time savings – with CROs investing 10% more than sponsors. As such, the research found that CROs complete all site-related activities 6 to 11 weeks faster than sponsors.

However, 80% of respondents still indicated a need to improve tools and technology to enable more effective processes, with 30-40% of respondents reporting they are unsatisfied with their processes. Those who did report a high level of satisfaction with their processes have 57.5% shorter cycle times, according to the report.

Additionally, across sponsors and CROs, average cycle times are 9.9 weeks shorter (28%) at repeat sites than at new sites.

It’s difficult to understand why there is so much variation and why there are so many inefficiencies and delays in study start-up, this was the impetus behind this research​,” said Craig Morgan, head of marketing at goBalto.

Numerous factors can adversely impact study startup and its efficiency, in an industry plagued by rising development costs and increasing complexities​,” he told us.

Some of these challenges include complex protocols, protocol amendments​, competition for sites, contract negotiations, regulatory changes and investigator​ and CRA turnover​, among others.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars